| Quantity: | |
|---|---|
Exemplar latitudinis librarium — Allergen (OVA, HDM, Fel d 1) adjuvant-compositae (LPS, c-di-GMP), et TSLP-acti (MC903) exempla eosinophilica, neutrophilica, et asthma granulocytici mixta endotypa.
Multiplices species/sonus — BALB/c (Th2-pronus), C57BL/6 (Th1/Th17-pronus), et muries humaniores praesto sunt.
Fines comprehendi - Corpus pondus, hyperresponsivitas airway (Penh, resistentia), BALF cellae comites (eosinophili, neutrophili, macrophages), serum IgE/allergen-specificum IgE, cytokinum profiling (IL-4, IL-5, IL-13, IL-17), pulmonis histopathologia (HE, Masson, PAS), hematologia.
Valor translationalis - Idealis ad probationes biologicas (anti-IL-4Rα, anti-IL-5, anti-IL-13), JAK inhibitores, corticosteroides et bronchodilatores.
IND-parati fasciculi notati - Studia administrari possunt ad normam GLP principiorum.
OVA Asthma inductus exemplar in C57BL/6 Mures
OVA inductus Asthma Model in Balb / c Mures
OVA inductus asthma exemplar murium
OVA+MC903 Asthma exemplar inductum in C57BL/6 Mures
OVA+LPS Neutrophilic asthma Exemplar inductus in C57BL/6 Mures
HDM Suscepit Asthma exemplar in C57BL/6 Mures
HDM Suscepit Asthma Model in IL4/IL4R Mures
HDM+LPS Inductus Asthma Model in C57BL/6 Mures
HDM + c-di-GMP Asthma exemplar inductum in C57BL/6 Mice
Fel d 1 Asthma Exemplar inductus in Balb/c Mures
• efficacia experimenti biologicorum (anti-IL-4Rα, anti-IL-5, anti-IL-13, anti-TSLP, anti-IL-33).
• Aestimatio inhibitores minoris moleculi (JAK inhibitores, PDE4 inhibitores, CRTH2 antagonistae)
• Target sanatio pro Th2, Th17, et epithelial-cytokini meatus
• Biomarker inventio (IgE, cytokina signatura, eosinophil/neutrophil venalicium)
• IND - pharmacologiam et toxicologiam studiis
Parameter |
Specificatio |
Species/Strain |
Mus (BALB/c, C57BL/6, HIS humanatus) |
modus inductionis |
OVA alum MC903 ± LPS; HDM ± c-di-GMP; Fel d 1 + alum |
Studium durationis |
3-8 weeks (sensitization + provocatione augmenta) |
Clavis terminos |
Corpus pondus, hyperresponsivitas airway (invasiva/non-invasiva), cytologia BALF (eosinophila, neutrophila, macrophages), serum totalium IgE & allergen-specificum IgE, gradus cytokini (IL-4, IL-5, IL-13, IL-17, IFN-γ), pulmonis histopathologia (HE, Masson, PAS) cum scoring. |
Data sarcina |
Rudis notitia, analysis nuntiationum, BALF cellulae comites, ELISA eventus, histologia labitur, munus data pulmonis, bioinformatica (libitum) |
Q: Quomodo eligo exemplar ius AD medicamentum meum candidatum?
A: Pone mechanismum pharmacum tuum: Th2‑targeted biologici (eg, anti‑IL‑4Rα) optime aestimantur in exemplaribus hapten vel MC903; Composita cognata Th17 vel HDM+SEB exemplaribus IL‑36 vel HDM+ accommodata esse possunt. Mures BALB/c responsa Th2 fortiores exhibent, cum C57BL/6 plus librationis perfiles Th1/Th17 ostendunt. Nostra turma scientifica exemplum lectionis in scopo tuo specifico dirigere potest.
Q: Potestne haec exempla adhiberi ad studia indeclinabilia?
A: Ita. Studia peragi possunt secundum principia GLP pro submissionibus moderantibus (FDA, EMA).
Q: Tu nativus studiorum protocolla praebes (exempli gratia, varias dosing cedulas, iuncturas therapias)?
A: Absolute. Nostrae turmae sartores scientificae inductionis protocolla, cedulas curationum, et analyses analysi ad specificum pharmacum candidatum.
Q: Quid est typicam timeline pro gubernator efficacia studio?
A: Pleraque AD exempla intra 2-4 septimanas complent, inter sensum/provocationem et augmenta curationum. Specia tempora pendent ab exemplaribus electionibus et terminis.
